Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Screening, surgical cure and new developments: Current state of the art surgery

Future Horizons in Lung Cancer

Sorry, this item is currently unavailable.

Published: 5 Oct 2016

Views: 1975

Rating:

Save

Dr Ugo Pastorino - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Dr Pastorino presents at the Future Horizons in Lung Cancer meeting about current state of the art surgery in lung cancer.

Related Videos

TROP2 expression measured by QCS is a promising predictor of clinical outcomes...

Dr Marina Garassino - University of Chicago, Chicago, USA

TROP2 expression measured by QCS is a promising predictor of clinical outcomes in patients with mNSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

Biomarkers, predictive and prognostic factors of resistance to immunotherapy

Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...

Biomarkers, predictive and prognostic factors of resistance to immunotherapy ( Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain )

Uncommon genetic aberrations NTRK, RET, NRG

Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA

Uncommon genetic aberrations NTRK, RET, NRG ( Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA )

Innovative treatments for solid tumours – TTFields as a therapeutic modality

Dr Giuseppe Lombardi, Dr Helen Bulbeck, Prof Dean Fennell and Dr Tadeja Urbanic...

Innovative treatments for solid tumours – TTFields as a therapeutic modality ( Dr Giuseppe Lombardi, Dr Helen Bulbeck, Prof Dean Fennell and Dr Tadeja Urbanic-Purkart )

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during...

Prof Gerard Zalcman - Université de Paris, Paris, France

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients ( Prof Gerard Zalcman - Université de Paris, Paris, France )

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall...

Dr Neil Gross - MD Anderson Cancer Center, Houston, USA

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC ( Dr Neil Gross - MD Anderson Cancer Center, Houston, USA )

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

The 5-year long-term outcomes of radiation technique for locally advanced NSCLC

Dr Stephen Chun - MD Anderson, Houston, USA

The 5-year long-term outcomes of radiation technique for locally advanced NSCLC ( Dr Stephen Chun - MD Anderson, Houston, USA )

War in Ukraine: The Global Medical Knowledge Alliance's response to improving...

Prof Richard Sullivan, Asst. Prof Darya Kizub and Asst. Prof Nelya Melnitchouk

War in Ukraine: The Global Medical Knowledge Alliance's response to improving cancer care ( Prof Richard Sullivan, Asst. Prof Darya Kizub and Asst. Prof Nelya Melnitchouk )

More from ecancer